Beta Bionics, Inc. (BBNX)
(Delayed Data from NSDQ)
$16.40 USD
-0.39 (-2.32%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $16.39 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BBNX 16.40 -0.39(-2.32%)
Will BBNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BBNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BBNX
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
BBNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BBNX
Beta Bionics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Beta Bionics (BBNX) Receives Target Price Upgrade from Truist Securities | BBNX Stock News
BBNX Analyst Rating Update: Price Target Raised by Baird | BBNX Stock News
Beta Bionics (BBNX) Price Target Raised Amid Strong Q2 Performance